Morgan Stanley Downgrades JD Health International to Underweight From Equal-weight; Price Target Is HK$20.40
01:21 AM EDT, 07/17/2024 (MT Newswires) -- Morgan Stanley Downgrades JD Health International to Underweight From Equal-weight; Price Target is HK$20.40
JD Health (06618) granted 1.1038 million shares of incentive stock.
jd health (06618) announced that on July 1, 2024, the company will grant shares in accordance with the first public offering...
Hong Kong Shares Rebound 2.9% Amid Positive Sentiment
Hong Kong's Hang Seng Index extended early gains to close 2.9% higher at 18430.39. There could be some optimism among investors that more may be done by the Chinese authorities in 2H, IG market strate
Hang Seng Index Likely to Consolidate Between 18500-20000 Near Term
0642 GMT - Hong Kong's Hang Seng Index is likely to consolidate between 18500 and 20000 in the near term, according to CCB International analysts Cliff Zhao and Wilson Zou in a research note. They say
Market Chatter: JD.com's Healthcare Arm Shuttering Family Doctor Initiative
Chinese e-commerce giant JD.com (HKG:9618) closed its healthcare arm JD Health International's (HKG:6618) family doctor division after failing to turn a profit, Yicai Global reported Tuesday, citing a
Despite slow growth, Ali Health is gradually becoming “healthy”
Jinwu Financial News | On May 27, Alibaba Health (00241.HK) announced its annual results for the 2024 fiscal year ending March 31, 2024. During the reporting period, it achieved revenue of 27.027 billion yuan, a slight increase of 1.0% year on year, and realized net profit of 883 million yuan, an increase of 64.6% year on year, with a significant increase in profit against the backdrop of flat revenue growth. The number of members of over 77 million and a MAU of up to 300 million have made Ali Health's current earnings report very popular. Driven by the results, Alibaba Health Hong Kong stock surged 10% on the 28th.
Trending Industry Today: ALI HEALTH Leads Gains In Digital Health Stocks
May 28th - The industry of $Digital Health(LIST1251.HK)$ is trending higher today with 4 constituents up and ALI HEALTH leading Gains.$ALI HEALTH(00241.HK)$ rises 11.72% to HK$3.43 with a turnover of
SciNet shares, Pusheng Ali Health (00241), rose 12.05%, and UBS's views on Chinese stocks turned positive, favoring Technet stocks, etc.
Jinwu Financial News | SciNet stocks rose 12.05%, JD Health (06618) rose 5.15%, Shell (02423) rose 2.5%, Baidu (09888) rose 1.22%, followed by Tencent (00700), Bilili (09626), and Alibaba (09988).
JD Health (06618) issues 350,000 shares under the initial public offering after-sale share incentive plan
JD Health (06618) issued an announcement on May 17, 2024, as adopted on November 2, 2020...
[Hong Kong Stock Connect] JD Health (06618) turned 2.58%. Non-IFRS operating profit fell 34.8% in the first quarter
Jinwu Financial News | JD Health (06618) fluctuated and declined. It once rose more than 2.4% in early trading and fell as low as 3.07% in the afternoon. As of press release, it was reported at HK$30.15, still down 2.58%, with a turnover of HK$236 million. JD Health announced that for the three months ended March 31, 2024, non-IFRS operating profit was 754 million yuan (RMB, same below), a year-on-year decrease of 34.8%; operating profit of 487 million yuan, a decrease of 38.7%; and revenue of 13.267 billion yuan, a decrease of 4.9%.
JD Health (06618) Announces First Quarter Results Non-IFRS Operating Profit Reaches 754 Million Yuan
According to the Zhitong Finance App, JD Health (06618) announced results for the first quarter of 2024, with revenue of about 13.267 billion yuan, operating profit of about 487 million yuan, and non-IFRS operating profit of about 754 million yuan. In the first quarter of 2024, a number of new specialty drugs were launched at Jingdong Pharmacies; including Loctec (remegipan sulfate tablets), a new drug for targeted migraine treatment by Pfizer, and Xilida (rosulvastatin ezetimib tablets), a new combined fat-reducing drug under Sanofi. The company also continues to deepen cooperation with pharmaceutical companies such as Shanghai Pharmaceutical, Daiichi Sankyo, and Mandi Pharmaceutical to further strengthen it
2023 Annual Report
JD.com's 1Q Revenue Likely Supported by Low-Price Strategy, Better User Experience -- Market Talk
JD.com's low-price strategy and user experience enhancement likely sustained its gross merchandise value growth momentum and supported 1Q revenue growth, Daiwa analysts John Choi and Robin Leung say in a research note.
[Broker Focus] Tianfeng Securities maintains JD Health (06618) “buy” rating and is optimistic about the continued penetration of active users and the guarantee of omni-channel supply chain capabilities
Jinwu Financial News | According to Tianfeng Securities Research, JD Health (06618) achieved operating revenue of 53.5 billion yuan in 2023, an increase of 14.5% over 46.7 billion yuan in the same period last year; by business, the company's own product revenue in 2023 was 45.65 billion yuan, up 13.1% year on year; service revenue was 7.88 billion yuan, up 23.7% year on year. The company's gross margin increased by 1.0 pct to 22.2%, mainly due to changes in the product portfolio; annual profit was 2.14 billion yuan, up 459.2% year on year, and adjusted non-IFRS net profit reached 4.14 billion yuan, compared with 2
Nomura Adjusts JD Health's Price Target to HK$44 to HK$37, Keeps at Buy
05:00 AM EDT, 03/22/2024 (MT Newswires) -- Nomura Adjusts JD Health's Price Target to HK$44 to HK$37, Keeps at Buy Price (HKD): $28.05, Change: $-4.05, Percent Change: -12.62%
JD Health's 2023 Profit Soars Almost Sixfold to Over 2 Billion Yuan
JD Health International (HKG:6618) recorded a nearly sixfold surge in attributable profit for the year ended Dec. 31, 2023, to 2.14 billion yuan from 380.1 million yuan in 2022, a Wednesday filing on
[Hong Kong Stock Connect] JD Health (06618)'s profit of RMB 2,142 billion last year increased 463.49% year over year
Jinwu Financial News | JD Health (06618) announced that in 2023, the company's shareholders should account for profit of RMB 2,142 billion, an increase of 463.49% over the previous year; basic profit per share was 0.69 yuan. During the period, the company's revenue increased 14.5% from RMB 46.7 billion in 2022 to RMB 53.5 billion in 2023. In detail, the increase in the company's total revenue is mainly due to a 13.1% increase in product revenue from sales of pharmaceuticals and health products from RMB 40.4 billion in 2022 to RMB 45.7 billion in 2023. The main drivers for the growth of commodity revenue are
JD Health: 2023 Revenue Growth Driven by Higher Pharmaceutical and Healthcare Product Sales >6618.HK
JD Health: 2023 Revenue Growth Driven by Higher Pharmaceutical and Healthcare Product Sales >6618.HK
JD Health 2023 Rev CNY53.53B Vs. CNY46.74B >6618.HK
JD Health 2023 Rev CNY53.53B Vs. CNY46.74B >6618.HK
JD Health (06618) announced annual results, profit attributable to shareholders of 2.42 billion yuan, a sharp increase of 463.49% year-on-year, and the average number of online consultations throughout the year has exceeded 450,000
JD Health (06618) announced its annual results for the year ended December 31, 2023. The group will take...